Where is Novartis AG (NVS) Headed?

Novartis AG (NYSE:NVS) is 1 of the champion immunotherapy stocks to bargain according to hedge funds. Novartis AG (NYSE:NVS) announced connected February 13  final results from the Phase III ALIGN study, stating that Vanrafia (atrasentan) showed a affirmative quality successful eGFR alteration from baseline vs. placebo astatine Week 136 successful the ALIGN study, 4 weeks aft survey attraction ended, with results favoring Vanrafia crossed aggregate timepoints, measures of kidney function, and successful patients additionally receiving SGLT2 inhibitors. Management reported that clinically meaningful results were observed compared to placebo successful eGFR alteration from baseline astatine the extremity of survey attraction astatine Week 132, and successful the prespecified exploratory radical of patients additionally receiving sodium-glucose co-transporter-2 inhibitors.

Vanrafia attained accelerated support successful the U.S. and China for the simplification of proteinuria successful adults with IgAN successful 2025, and Novartis AG (NYSE:NVS) has plans to taxable for accepted support successful 2026. The institution added that ALIGN offers the longest follow-up play successful pivotal Phase III studies for IgAN3, and that information was accordant with erstwhile findings. In summation to Vanrafia, Novartis AG (NYSE:NVS) is continually advancing its multi-asset IgAN portfolio, including Fabhalta and investigational compound zigakibart.

In a abstracted development, JPMorgan lifted the terms people connected Novartis AG (NYSE:NVS) to CHF 135 from CHF 125 connected February 12, maintaining an Overweight standing connected the shares.

Headquartered successful Basel, Switzerland, Novartis AG (NYSE:NVS) develops, markets, and manufactures a scope of healthcare and pharmaceutical products, and is besides progressive successful immuno-oncology research. Its operations span the Innovative Medicines, Sandoz, and Corporate segments.

While we admit the imaginable of NVS arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.